logo-loader
Polarean Imaging PLC

Appointment of Chief Financial Officer

/**/ link{ color: #0563C1 }visited{ color: #954F72 } .q{size:595.0pt 841.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.q{}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";}span.ap{font-size:11.0pt}p.ar{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.ao{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.an{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.as{margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}p.at{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}p.au{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold} p.av{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align:justify;text-justify:inter-ideograph}p.aw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-div: italic; text-align: justify; text-justify: inter-ideograph}p.ax{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify; text-justify: inter-ideograph}span.ag{font-size:11.0pt;color:black}table.ay{width:459.9pt;margin-left:-5.4pt;border-collapse:collapse}td.ae{width:228.6pt;padding:0cm 5.4pt 0cm 5.4pt}td.ac{width:209.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.az{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align: right}td.ab{width:315.0pt;padding:0cm 5.4pt 0cm 5.4pt}td.z{width:123.3pt;padding:0cm 5.4pt 0cm 5.4pt} p.ba{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-div: italic; text-align: right}p.bb{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: right}td.x{width:174.6pt;padding:0cm 5.4pt 0cm 5.4pt}td.v{width:263.7pt;padding:0cm 5.4pt 0cm 5.4pt}span.w{font-size: 11.0pt}td.u{width:201.6pt;padding:0cm 5.4pt 0cm 5.4pt}td.t{width:236.7pt;padding:0cm 5.4pt 0cm 5.4pt}td.s{border:none} /**/
RNS Number : 2716X
Polarean Imaging PLC
29 April 2019
 

29 April 2019

Polarean Imaging Plc 

("Polarean" or the "Company")

 

Appointment of Chief Financial Officer

 

Polarean Imaging plc (AIM: POLX) Polarean Imaging plc (AIM: POLX), the clinical stage medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces the appointment of Charles (Chuck) Osborne, Jr as Chief Financial Officer (CFO) with immediate effect. Chuck Osborne's role is a non-board appointment.

 

Mr. Osborne joins the Company from Innocrin Pharmaceuticals Inc ("Innocrin"), a privately held oncology therapeutics company where he was CFO since 2015. Prior to his role at Innocrin, Mr. Osborne was CFO of Scynexis Inc, a publicly traded anti-infective company between 2003 and 2015.  Mr. Osborne holds a Bachelor of Science degree in Business Administration, with a Concentration in Accounting, from University of North Carolina. He is a Certified Public Accountant and began his accounting career at Deloittie & Touche in 1988. 

 

Mr. Osborne will replace the Company's current CFO Bill Patrick, who will stay with Polarean in the role of Financial Controller to Polarean Inc, the Company's wholly owned subsidiary. 

 

Richard Hullihen, CEO of Polarean Imaging, commented on the appointment: "We are delighted to welcome Chuck to Polarean's management team. Chuck's previous capital markets experience coupled with his knowledge of financial operations within the pharmaceutical industry will ensure strong leadership of the Company's financial function.

 

"On behalf of the Board, I would like to thank Bill Patrick for all his efforts and input to date both operationally and financially through the Company's admission to AIM last year and in the period since. Mr Patrick's involvement with the Company will continue with his new role of Financial Controller for Polarean Inc."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Richard Morgan, Chairman




SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)




Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

 

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOAPGUCUCUPBGGQ

Quick facts: Polarean Imaging PLC

Price: £0.24

Market: AIM
Market Cap: £27.64 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging begins enrolment for phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site. The company’s drug-device...

2 weeks, 3 days ago

RNS

Phase III Clinical Trials update

2 weeks, 4 days ago

Total Voting Rights

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Result of AGM

4 weeks, 1 day ago

Exercise of Warrants

4 weeks, 2 days ago